Organization
Swedish Medical Center and University of Washington, Seattle, WA, United States of america
3 abstracts
Abstract
ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETSOrg: Nuffield Orthopaedic Centre, Oxford, United Kingdom, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States of america, St Vincent’s University Hospital and Conway institute for Biomolecular Research, University College Dublin, Dublin, Ireland, Division of Rheumatology allergy and Immunology, UC San Diego School of Medicine, La Jolla, CA, United States of america, Department of Dermatology, ICahn School of Medicine at Mt Sinai, New York, NY, United States of america,
Abstract
BIOLOGIC THERAPY, TIME TO LOW DISEASE ACTIVITY, AND EFFECT OF MONO VS. BACKGROUND ORAL DMARD THERAPY AMONG PSORIATIC ARTHRITIS PATIENTS IN A US REGISTRY. Org: Swedish Medical Center and University of Washington, Seattle, WA, United States of america, Amgen, Inc., Thousand Oaks, CA, CORRONA, Inc., Southborough, MA, Axio Research, LLC, Seattle, WA, Amgen, Inc., San Francisco, CA,
Abstract
BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITISOrg: Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of america, UZ Leuven, Leuven, Belgium, Pfizer Inc, Groton, CT, United States of America, Swedish Medical Center and University of Washington, Seattle, WA, United States of america, Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, United States of america,